Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
Allergy Therapeutics plc (AGYTF) - Net Assets
Latest net assets as of June 2025: $-63.88 Million USD
Based on the latest financial reports, Allergy Therapeutics plc (AGYTF) has net assets worth $-63.88 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($67.54 Million) and total liabilities ($131.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-63.88 Million |
| % of Total Assets | -94.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | -231.62% |
| 10-Year Change | -310.67% |
| Growth Volatility | 431.79 |
Allergy Therapeutics plc - Net Assets Trend (2002–2025)
This chart illustrates how Allergy Therapeutics plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Allergy Therapeutics plc (2002–2025)
The table below shows the annual net assets of Allergy Therapeutics plc from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-63.88 Million | -1822.39% |
| 2024-06-30 | $3.71 Million | +79.53% |
| 2023-06-30 | $2.07 Million | -94.62% |
| 2022-06-30 | $38.40 Million | -20.89% |
| 2021-06-30 | $48.53 Million | +10.85% |
| 2020-06-30 | $43.78 Million | +16.57% |
| 2019-06-30 | $37.56 Million | +63.05% |
| 2018-06-30 | $23.03 Million | -23.13% |
| 2017-06-30 | $29.96 Million | -1.18% |
| 2016-06-30 | $30.32 Million | -12.03% |
| 2015-06-30 | $34.47 Million | +128.65% |
| 2014-06-30 | $15.07 Million | +2.75% |
| 2013-06-30 | $14.67 Million | +0.54% |
| 2012-06-30 | $14.59 Million | +582.19% |
| 2011-06-30 | $2.14 Million | -44.96% |
| 2010-06-30 | $3.89 Million | +116.77% |
| 2009-06-30 | $-23.18 Million | -105.28% |
| 2008-06-30 | $-11.29 Million | -231.34% |
| 2007-06-30 | $8.60 Million | -73.71% |
| 2006-06-30 | $32.70 Million | +62.83% |
| 2005-06-30 | $20.08 Million | +183.83% |
| 2004-06-30 | $7.08 Million | +27.56% |
| 2003-06-30 | $5.55 Million | +226.13% |
| 2002-06-30 | $-4.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Allergy Therapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22818453400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.54 Million | % |
| Other Comprehensive Income | $10.30 Million | % |
| Other Components | $212.29 Million | % |
| Total Equity | $-38.70 Million | 100.00% |
Allergy Therapeutics plc Competitors by Market Cap
The table below lists competitors of Allergy Therapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thai Optical Group Public Company Limited
BK:TOG
|
$25.30 Million |
|
ATA Creativity Global
NASDAQ:AACG
|
$25.30 Million |
|
Haulotte Group SA
PA:PIG
|
$25.32 Million |
|
Multicampus Corporation
KQ:067280
|
$25.32 Million |
|
KSP Co. Ltd.
KQ:073010
|
$25.30 Million |
|
Chia Her Industrial Co Ltd
TW:1449
|
$25.29 Million |
|
STRUCT.MONIT.SYSCDIS
F:RJP
|
$25.29 Million |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
$25.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allergy Therapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,709,000 to -38,703,350, a change of -42,412,350 (-1143.5%).
- Net loss of 55,093,209 reduced equity.
- Other comprehensive income decreased equity by 32,934,999.
- Other factors increased equity by 45,615,858.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.09 Million | -142.35% |
| Other Comprehensive Income | $-32.93 Million | -85.1% |
| Other Changes | $45.62 Million | +117.86% |
| Total Change | $- | -1143.50% |
Book Value vs Market Value Analysis
This analysis compares Allergy Therapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-06-30 | $-0.10 | $0.10 | x |
| 2003-06-30 | $0.09 | $0.10 | x |
| 2004-06-30 | $0.14 | $0.10 | x |
| 2005-06-30 | $0.16 | $0.10 | x |
| 2006-06-30 | $0.23 | $0.10 | x |
| 2007-06-30 | $0.05 | $0.10 | x |
| 2008-06-30 | $-0.06 | $0.10 | x |
| 2009-06-30 | $-0.11 | $0.10 | x |
| 2010-06-30 | $0.01 | $0.10 | x |
| 2011-06-30 | $0.00 | $0.10 | x |
| 2012-06-30 | $0.02 | $0.10 | x |
| 2013-06-30 | $0.01 | $0.10 | x |
| 2014-06-30 | $0.01 | $0.10 | x |
| 2015-06-30 | $0.03 | $0.10 | x |
| 2016-06-30 | $0.02 | $0.10 | x |
| 2017-06-30 | $0.02 | $0.10 | x |
| 2018-06-30 | $0.02 | $0.10 | x |
| 2019-06-30 | $0.03 | $0.10 | x |
| 2020-06-30 | $0.03 | $0.10 | x |
| 2021-06-30 | $0.03 | $0.10 | x |
| 2022-06-30 | $0.03 | $0.10 | x |
| 2023-06-30 | $0.00 | $0.10 | x |
| 2024-06-30 | $0.00 | $0.10 | x |
| 2025-06-30 | $-0.01 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allergy Therapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -72.91%
- • Asset Turnover: 1.12x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-147.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | -30.80% | 1.56x | 0.00x | $-4.02 Million |
| 2003 | 93.31% | 29.87% | 1.55x | 2.01x | $4.62 Million |
| 2004 | 17.21% | 6.77% | 1.60x | 1.59x | $510.40K |
| 2005 | -10.91% | -10.63% | 0.77x | 1.33x | $-4.20 Million |
| 2006 | -18.88% | -26.20% | 0.62x | 1.16x | $-9.44 Million |
| 2007 | -270.54% | -90.34% | 1.07x | 2.79x | $-24.12 Million |
| 2008 | 0.00% | -65.43% | 1.34x | 0.00x | $-19.17 Million |
| 2009 | 0.00% | -31.16% | 1.71x | 0.00x | $-9.45 Million |
| 2010 | 15.08% | 1.44% | 1.40x | 7.49x | $197.40K |
| 2011 | -124.45% | -6.41% | 1.36x | 14.32x | $-2.88 Million |
| 2012 | 5.64% | 1.99% | 1.49x | 1.90x | $-636.20K |
| 2013 | 4.31% | 1.61% | 1.36x | 1.97x | $-834.10K |
| 2014 | 4.92% | 1.77% | 1.48x | 1.88x | $-766.50K |
| 2015 | 0.31% | 0.25% | 0.85x | 1.47x | $-3.34 Million |
| 2016 | -43.11% | -26.95% | 0.86x | 1.87x | $-16.10 Million |
| 2017 | -8.28% | -3.87% | 1.12x | 1.91x | $-5.48 Million |
| 2018 | -32.70% | -11.02% | 1.34x | 2.21x | $-9.84 Million |
| 2019 | 9.23% | 4.70% | 1.08x | 1.82x | $-288.80K |
| 2020 | 16.12% | 9.03% | 0.91x | 1.97x | $2.68 Million |
| 2021 | 5.95% | 3.42% | 0.96x | 1.81x | $-1.97 Million |
| 2022 | -36.48% | -18.93% | 0.99x | 1.95x | $-17.55 Million |
| 2023 | -2084.75% | -72.28% | 0.89x | 32.32x | $-43.28 Million |
| 2024 | -1084.28% | -72.86% | 0.85x | 17.48x | $-40.59 Million |
| 2025 | 0.00% | -72.91% | 1.12x | 0.00x | $-51.22 Million |
Industry Comparison
This section compares Allergy Therapeutics plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $609,160,015
- Average return on equity (ROE) among peers: -268.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allergy Therapeutics plc (AGYTF) | $-63.88 Million | 0.00% | N/A | $25.30 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |